home *** CD-ROM | disk | FTP | other *** search
- <text id=89TT2023>
- <title>
- Aug. 07, 1989: Friendly Medicine
- </title>
- <history>
- TIME--The Weekly Newsmagazine--1989
- Aug. 07, 1989 Diane Sawyer:Is She Worth It?
- </history>
- <article>
- <source>Time Magazine</source>
- <hdr>
- BUSINESS, Page 39
- Friendly Medicine
- </hdr><body>
- <p> Are friendly mergers back in vogue? Just three days after
- the Delaware Supreme Court gave Time Inc. and Warner
- Communications the go-ahead to join forces, another megamerger
- was announced. Bristol-Myers (1988 sales: $6 billion) and Squibb
- ($2.6 billion) said they had agreed to an $11.2 billion stock
- swap that would create the world's second largest drug company.
- The friendly merger would be the largest so far in the current
- race to create globe-spanning pharmaceutical giants. The new
- company, with headquarters in Manhattan, would bring together
- such products as Bristol-Myers' Bufferin painkiller and Windex
- glass cleaner with Squibb's Capoten, a leading prescription
- formula for heart ailments.
- </p>
- <p> The Delaware court rulings have created a more cordial
- climate for such deals. Before Time and Warner were allowed to
- consolidate, many companies feared that an agreement to merge
- would be tantamount to putting themselves up for sale. But the
- Delaware courts affirmed the right of corporate directors to
- pursue long-term strategies. Says Harvard law professor Reinier
- Kraakman of the new precedent: "This gives managers who are
- planning a friendly acquisition or a merger of equals a chance
- to go forward without losing out to a hostile acquirer."
- </p>
- <p> For Squibb and Bristol-Myers a consolidation seemed a
- natural. It would weld Squibb's skill at research and
- development with its partner's worldwide sales force. "There is
- pressure on health-care costs throughout the world. U.S.
- companies are merging to obtain efficiencies of scale," says
- David Lippman, who follows the industry for Drexel Burnham
- Lambert.
- </p>
- <p> In another deal that was driven by global ambitions,
- shareholders of SmithKline Beckman, developer of the anti-ulcer
- drug Tagamet, last week approved a merger with London's Beecham
- Group, which has built strong European markets. One week
- earlier Dow Chemical agreed to merge its Merrell Dow
- Pharmaceuticals subsidiary with Marion Laboratories, whose chief
- prescription drug is Cardizem, an angina treatment. In the
- afterglow of the Time-Warner marriage and other such deals,
- companies in many industries may gain greater confidence to
- embark on friendly combinations.
- </p>
-
- </body></article>
- </text>
-
-